Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Warby Parker Inc.
WRBY
NYSE·Healthcare·Medical - Instruments & Supplies·Mkt cap $3.6B
$29.15
▼ -0.75%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$14.96 - $31.00
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 33.7% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Vertically integrated supply chain reducing costs and enabling competitive pricing
- Strong direct-to-consumer brand with high customer loyalty and repeat purchase rates
- Omnichannel retail presence combining e-commerce, mobile apps, and physical stores
- In-house eye exam capabilities reducing dependence on third-party optometrists
- Proprietary technology platform for virtual try-on and prescription management
Bear Case
2 risks
- Above-average volatility (beta 2.0).
- Extreme premium - high expectations embedded
Growth
Moderate growth ahead
Expansion of retail store footprint in underserved markets across North America
Value
Extreme premium - high expectations embedded
Momentum
Hot
+44.8% over 3m
Quality
Strong
Exceptional business - top-tier fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying WRBY right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: May 6, 2026
MAY 7, 2026
Reported EPS of $0.12 vs $0.11 consensus (+9.1% surprise). Revenue of $242.4M vs $239.4M expected (+1.3%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+9.1%
Next: May 6, 2026
Revenue trend · last 8Q
—
—
+18%
+12%
+14%
+15%
+11%
+8%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$188.2M
$192.4M
$190.6M
$223.8M
$214.5M
$221.7M
$212.0M
$242.4M
Margins · last 8Q
Gross
—
Operating
—
Profit
1.3%
Wall Street consensus
4 analysts · 50% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
50%
Hold
50%
Sell
0%
Median Price Target
$31.50
▲ +8.1% vs $29.15
Latest: China Renaissance Securities (US) · $30.00 · May 22, 2026
4 analysts covering